Viewpoint | Published:

Fenretinide and risk reduction of second breast cancer

Nature Clinical Practice Oncology volume 4, pages 6465 (2007) | Download Citation

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    et al. (2004) How retinoids regulate breast cancer cell proliferation and apoptosis. Cell Mol Life Sci 61: 1475–1484

  2. 2.

    et al. (1995) Modulation of markers associated with tumor aggressiveness in human breast cancer cell lines by N-(4-hydroxyphenyl) retinamide. Cell Growth Differ 6: 863–869

  3. 3.

    et al. (1995) Contralateral breast cancer: annual incidence and risk parameters. J Clin Oncol 13: 1578–1583

  4. 4.

    et al. (1999) Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer. J Natl Cancer Inst 91: 1847–1856

  5. 5.

    et al. (2002) Effect of fenretinide on ovarian carcinoma occurrence. Gynecol Oncol 86: 24–27

  6. 6.

    et al. (2006) Fifteen-year results of a randomized phase III trial of fenretinide to prevent second breast cancer. Ann Oncol 7: 1065–1071

  7. 7.

    et al. (1997) Insulin-like growth factor-binding proteins in serum and other biological fluids: regulation and functions. Endocr Rev 18: 801–831

  8. 8.

    et al. (2003) Relationships between plasma insulin-like growth factor-I and insulin-like growth factor binding protein-3 and second breast cancer risk in a prevention trial of fenretinide. Clin Cancer Res 9: 2032–2039

  9. 9.

    et al. (2005) Sensitivity to DNA damage is a common component of hormone-based strategies for protection of the mammary gland. Mol Cancer Res 8: 435–442

  10. 10.

    et al. (2005) N-(4-Hydroxyphenyl) retinamide is more potent than other phenylretinamides in inhibiting the growth of BRCA1-mutated breast cancer cells. Carcinogenesis 26: 1000–1007

  11. 11.

    et al. (1992) Comparative teratogenicity of nine retinoids in the rat. Int J Exp Pathol 73: 551–563

Download references

Author information

Affiliations

  1. A Decensi is Director of, and S Zanardi and A Argusti work in, the Division of Medical Oncology, E.O. Ospedali Galliera, Genoa. B Bonanni is Co-Director of the Division of Chemoprevention, and U Veronesi is Scientific Director of the European Institute of Oncology, and A Costa is Director of the European School of Oncology, Milan, Italy.

    • Andrea Decensi
    • , Silvia Zanardi
    • , Alessandra Argusti
    • , Bernardo Bonanni
    • , Alberto Costa
    •  & Umberto Veronesi

Authors

  1. Search for Andrea Decensi in:

  2. Search for Silvia Zanardi in:

  3. Search for Alessandra Argusti in:

  4. Search for Bernardo Bonanni in:

  5. Search for Alberto Costa in:

  6. Search for Umberto Veronesi in:

Competing interests

The authors declare no competing financial interests.

Corresponding author

Correspondence to Andrea Decensi.

Supplementary information

About this article

Publication history

Received

Accepted

Published

DOI

https://doi.org/10.1038/ncponc0735

Further reading

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing